FY2029 Earnings Forecast for INKT Issued By HC Wainwright

MiNK Therapeutics, Inc. (NASDAQ:INKT) – Investment analysts at HC Wainwright issued their FY2029 earnings estimates for shares of MiNK Therapeutics in a report issued on Tuesday, February 25th. HC Wainwright analyst E. Bodnar expects that the company will post earnings per share of ($0.02) for the year. HC Wainwright has a “Buy” rating and a $35.00 price objective on the stock. The consensus estimate for MiNK Therapeutics’ current full-year earnings is ($2.75) per share.

Separately, Robert W. Baird cut their target price on MiNK Therapeutics from $80.00 to $40.00 and set an “outperform” rating on the stock in a research report on Friday, November 15th.

MiNK Therapeutics Stock Down 0.6 %

NASDAQ:INKT opened at $9.26 on Wednesday. MiNK Therapeutics has a 52 week low of $4.56 and a 52 week high of $19.00. The company has a market capitalization of $36.69 million, a P/E ratio of -2.37 and a beta of 0.17. The stock’s fifty day moving average is $8.47 and its two-hundred day moving average is $7.74.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.